Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach DOI Creative Commons
Paweł Zieliński, Maria Stępień, Hanna Chowaniec

и другие.

Cells, Год журнала: 2025, Номер 14(8), С. 587 - 587

Опубликована: Апрель 12, 2025

Lung cancer with the highest number of new cases diagnosed in Europe and Poland, remains an example malignancy a very poor prognosis despite recent progress medicine. Different treatment strategies are now available for therapy based on its type, molecular subtype other factors including overall health, stage disease profile. Immunotherapy is emerging as potential addition to surgery, chemotherapy, radiotherapy or targeted therapies, but also considered mainstay mode. This combination area active investigation order enhance efficacy overcome resistance. Due complexity dynamic cancer’s ecosystem, novel therapeutic targets need continued research into cellular mechanisms within tumour microenvironment. From genetic point view, several signatures ranging from few mutated genes hundreds them have been identified associated resistance metastatic potential. ML techniques AI can predictive model prognosis. Here, we present overview already existing approaches, current findings key aspects immunotherapy, such immune checkpoint inhibitors (ICIs), biomarkers like PD-L1 expression, mutation burden, immunoscore, neoantigens, well their roles markers response

Язык: Английский

Circulating Tumour DNA for Ovarian Cancer Diagnosis and Treatment Monitoring: What Perspectives for Clinical Use? DOI Open Access
Du-Bois Asante, Domenico Tierno, Gabriele Grassi

и другие.

International Journal of Molecular Sciences, Год журнала: 2025, Номер 26(5), С. 1889 - 1889

Опубликована: Фев. 22, 2025

Globally, ovarian cancer (OC) is the eighth most common malignant tumour in women. Unfortunately, its symptoms-especially at early stages-are vague and non-specific, and, thus, patients are diagnosed advanced stages of disease (stage III IV) when treatment not curative. The currently available approved biomarkers sufficient for effective screening, prognosis, or monitoring OC. Liquid biopsy tests such as circulating DNA (ctDNA) analysis has advantage response to real time providing a comprehensive genotypic profile primary, metastatic, recurrent tumours. Thus, ctDNA can be used complementary test diagnosis We comprehensively review current studies (2019-2024) on OC, critically highlighting recent developments applications management disease.

Язык: Английский

Процитировано

0
Clinical impact of sub-clonal RAS/BRAF alterations in liquid biopsies from patients with advanced or metastatic CRC DOI
Peter Gibbs,

Khalid Abubaker,

Danyi Wang

и другие.

Clinical Colorectal Cancer, Год журнала: 2025, Номер unknown

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Targeting VEGF signaling for tumor microenvironment remodeling and metastasis inhibition: Therapeutic strategies and insights DOI
Hanie Mahaki, Sima Nobari, Hamid Tanzadehpanah

и другие.

Biomedicine & Pharmacotherapy, Год журнала: 2025, Номер 186, С. 118023 - 118023

Опубликована: Апрель 2, 2025

Язык: Английский

Процитировано

0
Resistance in Lung Cancer Immunotherapy and How to Overcome It: Insights from the Genetics Perspective and Combination Therapies Approach DOI Creative Commons
Paweł Zieliński, Maria Stępień, Hanna Chowaniec

и другие.

Cells, Год журнала: 2025, Номер 14(8), С. 587 - 587

Опубликована: Апрель 12, 2025

Lung cancer with the highest number of new cases diagnosed in Europe and Poland, remains an example malignancy a very poor prognosis despite recent progress medicine. Different treatment strategies are now available for therapy based on its type, molecular subtype other factors including overall health, stage disease profile. Immunotherapy is emerging as potential addition to surgery, chemotherapy, radiotherapy or targeted therapies, but also considered mainstay mode. This combination area active investigation order enhance efficacy overcome resistance. Due complexity dynamic cancer’s ecosystem, novel therapeutic targets need continued research into cellular mechanisms within tumour microenvironment. From genetic point view, several signatures ranging from few mutated genes hundreds them have been identified associated resistance metastatic potential. ML techniques AI can predictive model prognosis. Here, we present overview already existing approaches, current findings key aspects immunotherapy, such immune checkpoint inhibitors (ICIs), biomarkers like PD-L1 expression, mutation burden, immunoscore, neoantigens, well their roles markers response

Язык: Английский

Процитировано

0